[1]陈慧姮,梁晓冬,邓婕,等.阿维A与甲氨蝶呤联合治疗难治性中重度银屑病疗效观察[J].中国皮肤性病学杂志,2018,(05):610-614.[doi:10.13735/j.cjdv.1001-7089.201708069]
 CHEN Huiheng,LIANG Xiaodong,DENG Jie,et al.Observation on the Efficacy of Acitretin Combined with Methotrexate on Refractory Moderate to Severe Psoriasis Vugaris[J].The Chinese Journal of Dermatovenereology,2018,(05):610-614.[doi:10.13735/j.cjdv.1001-7089.201708069]
点击复制

阿维A与甲氨蝶呤联合治疗难治性中重度银屑病疗效观察
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2018年05期
页码:
610-614
栏目:
药物与临床
出版日期:
2018-05-01

文章信息/Info

Title:
Observation on the Efficacy of Acitretin Combined with Methotrexate on Refractory Moderate to Severe Psoriasis Vugaris
作者:
陈慧姮梁晓冬邓婕薛如君梁景耀叶瑞贤张锡宝
广州医科大学皮肤病研究所/广州市皮肤病防治所, 广东 广州 510095
Author(s):
CHEN Huiheng LIANG Xiaodong DENG Jie XUE Rujun LIANG Jingyao YE Ruixian ZHANG Xibao
Institute of Dermatology, Guangzhou Medical University/Guangzhou Institute of Dermatology, Guangzhou 510095, China
关键词:
阿维A 甲氨蝶呤 银屑病 难治性 联合治疗 安全性
Keywords:
Acitretin Methotrexate Psoriasis Treatment-resistant Combined theraphy Safety
分类号:
R 758.63
DOI:
10.13735/j.cjdv.1001-7089.201708069
文献标志码:
A
摘要:
目的 探讨阿维A与甲氨蝶呤联合治疗难治性中重度银屑病的疗效及安全性。 方法 阿维A与甲氨蝶呤联合治疗12例难治性中重度银屑病患者24周,评估治疗期间治疗效果并监测用药不良反应。 结果 所有患者在24周治疗期内PASI评分逐渐下降(P<0.05),治疗16周时,达到PASI 75的患者占50.00%,达到PASI 50占83.33%; 24周时,PASI 50者为100%,PASI 75者为91.67%,所有患者均未发现明显不良反应。 结论 阿维A与MTX联合治疗难治性中重度银屑病的临床疗效明显,未发现不良反应。
Abstract:
Objective To evaluate the efficacy and safety of acitretin combined with methotrexate in treatment of refractory moderate to severe psoriasis vulgaris. Methods Twelve patients with moderate to severe psoriasis who were resistant to acitretin or methotrexate monotherapy were treated with acitretin combined with methotrexate for 24 weeks. The therapeutic effect was observed and adverse reactions of the multitherapy were monitored during the 24 weeks of treatment. Results The PASI score decreased in all patients during 24-week treatment(P<0.05). Specifically, 50% achieved PASI 75 and 83.3% achieved PASI 50 after 16 weeks of treatment. All patients showed remarkable curative response(100% patients with PASI 50, vs. 91.67% with PASI 75), at 24 weeks of treatment, and no adverse reactions were reported. Conclusion Acitretin combined with methotrexate is effective in the treatment of refractory moderate to severe psoriasis vulgaris and the adverse reactions of the multitherapy are not noted.

参考文献/References:

[1] Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al.Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients[J].J Clin Pharmacol, 1990, 30(9): 802-807.
[2] Rosenbaum MM, Roenigk HH.Treatment of generalized pustular psoriasis with etretinate(Ro 10-9359)and methotrexate[J].J Am Acad Dermatol, 1984, 10(2 Pt 2): 357-361.
[3] Malakouti M, Jacob SE, Anderson NJ.Treatment challenges in the management of moderate-to-severe plaque psoriasis-role of secukinumab[J].Clin Cosmet Investig Dermatol, 2016, 9(4): 347-355.
[4] Cantrell W.Psoriasis & psoriatic therapies[J].Nurse Pract, 2017, 42(7): 35-39.
[5] Cai Y, Fleming C, Yan J.New insights of T cells in the pathogenesis of psoriasis[J].Cell Mol Immunol, 2012, 9(4): 302-309.
[6] Armstrong AW, Koning JW, Rowse S, et al.Under-treatment of patients with moderate to severe psoriasis in the United States: Analysis of medication usage with health plan data[J].Dermatol Ther(Heidelb), 2017, 7(1): 97-109.
[7] Gottlieb AB.Therapeutic options in the treatment of psoriasis and atopic dermatitis[J].J Am Acad Dermatol, 2005, 53(1 Suppl 1): S3-16.
[8] An J, Zhang D, Wu J, et al.The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis[J].Pharmacol Res, 2017, 121(2): 158-168.
[9] Balighi K, Zahra GS, Azadeh G, et al.Assessment of the therapeutic aspect of systemic non-biologic anti-psoriatic treatment modalities used in combination with methotrexate[J].Indian Journal of Dermatology, 2016, 61(1):118.
[10] 李峰,晋红中,何志新,等.英夫利西单抗治疗17例中重度寻常性银屑病 [J].中华皮肤科杂志, 2016, 49(6):437-438.
[11] Thiers BH.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs.methotrexate vs.placebo in patients with psoriasis(CHAMPION)[J].Yearbook of Dermatology and Dermatologic Surgery, 2008, 158(3):558-566.
[12] van Vugt LJ, van den Reek J, Coenen MJH, et al.A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients[J].Br J Dermatol, 2017,178(1):86-94.

相似文献/References:

[1]杨颜龙,张禁,易松柏,等.阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病30例临床观察[J].中国皮肤性病学杂志,2015,(02):217.[doi:10.13735/j.cjdv.1001-7089.201403167]
 YANG Yan long,ZHANG Jin,YI Song bai,et al.Clinical Observation of 30 Acitretin Capsules Combine with Compound Glycyrrhizin Injection in the Treatment of Patients with Erythrodermic Psoriasis[J].The Chinese Journal of Dermatovenereology,2015,(05):217.[doi:10.13735/j.cjdv.1001-7089.201403167]
[2]隆岚,李振,钱振云,等.阿维A对寻常性银屑病患者CCL2和CCR2水平的影响[J].中国皮肤性病学杂志,2015,(10):1019.[doi:10.13735/j.cjdv.1001.7089.201503125]
 LONG Lan,LI Zhen,IAN Zhen yun,et al.Effects of Acitretin on CCL2 and CCR2 Levels in Patients with Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2015,(05):1019.[doi:10.13735/j.cjdv.1001.7089.201503125]
[3]桂欣钰,晋红中,方凯.阿维A联合环孢素治疗红皮病型银屑病并发外源性库欣综合征1例[J].中国皮肤性病学杂志,2016,(03):328.[doi:10.13735/j.cjdv.1001-7089.201507052]
 GUI Xin yu,JIN Hong zhong,FANG Kai.Combination Therapy with Acitretin and Cyclosporin A in a Patient with Erythrodermic Psoriasis and Exogenous Cushing Syndrome[J].The Chinese Journal of Dermatovenereology,2016,(05):328.[doi:10.13735/j.cjdv.1001-7089.201507052]
[4]邱会芬,王忠永,董大群,等.阿维A治疗前后寻常性银屑病患者外周血IL-23/TH17的水平[J].中国皮肤性病学杂志,2013,(09):893.
 QIU Huifen,WANG Zhongyong,DONG Daqun,et al.Effect of Acitretin on Level of IL23/Th17 in Peripheral Blood of Patients with Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2013,(05):893.
[5]刘磊吉,孙佳,任谦.阿维A对寻常性银屑病患者外周血中Th细胞相关趋化因子的影响[J].中国皮肤性病学杂志,2014,(11):1127.[doi:10.13735/j.cjdv.1001-7089.2014.1127]
 LIU Lei-ji,SUN Jia,REN Qian.Influence of Acitretin on the Levels of T Helper Chemokines in Patients with Psoriatic Vulgaris[J].The Chinese Journal of Dermatovenereology,2014,(05):1127.[doi:10.13735/j.cjdv.1001-7089.2014.1127]
[6]夏萍,童中胜,夏云,等.肥厚性红斑狼疮1例[J].中国皮肤性病学杂志,2014,(08):835.[doi:10.13735/j.cjdv.1001-7089.2014.0835]
 XIA Ping,TONG Zhong-sheng,XIA Yun,et al.A Case of Hypertrophic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2014,(05):835.[doi:10.13735/j.cjdv.1001-7089.2014.0835]
[7]张家华,刘毅,李征,等.阿维A联合紫外线治疗银屑病疗效的Meta分析[J].中国皮肤性病学杂志,2014,(12):1211.[doi:10.13735/j.cjdv.1001-7089.2014.1211]
 ZHANG Jia-hua,LIU Yi,LI Zheng,et al.Acitretin Combined with NB-UVB for Psoriasis: A Meta-analysis of Randomized Controlled Trials[J].The Chinese Journal of Dermatovenereology,2014,(05):1211.[doi:10.13735/j.cjdv.1001-7089.2014.1211]
[8]赵京霞,底婷婷,王燕,等.5种常用药物对咪喹莫特诱导小鼠银屑病样皮损模型形成的影响[J].中国皮肤性病学杂志,2014,(03):234.
 ZHAO Jing-xia,DI Ting-ting,WANG Yan,et al.Effect of Psoriasis Orientated Drugs on Psoriasis-like Mice Model Induced by Imiquimod[J].The Chinese Journal of Dermatovenereology,2014,(05):234.
[9]冯华,陈自学,倪文琼.阿维A治疗寻常性银屑病42例临床观察[J].中国皮肤性病学杂志,2014,(03):327.
 FENG Hua,CHEN Zi-xue,NI Wen-qiong.Observation of Acitretin Efficacy on 42 Cases with Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2014,(05):327.
[10]张大维,路永红,裴宝强,等.阿维A对瘢痕疙瘩成纤维细胞生长和凋亡的影响[J].中国皮肤性病学杂志,2018,(12):1373.[doi:10.13735/j.cjdv.1001-7089.201803117]
 ZHANG Dawei,LU Yonghong,PEI Baoqiang,et al.Influence of Acitretin on the Growth and Apoptosis of Keloid Fibroblasts[J].The Chinese Journal of Dermatovenereology,2018,(05):1373.[doi:10.13735/j.cjdv.1001-7089.201803117]

备注/Memo

备注/Memo:
[基金项目] 广东省自然科学基金(2016A030313471)
[通讯作者] 张锡宝,E-mail:zxibao@126.com
更新日期/Last Update: 2018-05-01